CPRD GOLD linked National Cancer Registration and Analysis Service (NCRAS) cancer registration data contain a record for each notified, registrable tumour, diagnosed or treated in England.

The English Cancer Patient Experience Survey (CPES) is commissioned by NHS England and administered on their behalf by an external survey provider organisation (Quality Health). The survey provides insights into the care experienced by cancer patients across England who were treated as day cases or inpatients. Data from CPES has been linked to cancer registration records recorded by the National Cancer Registration and Analysis Service (the cancer registry in England). Individual responses to Wave 1 of CPES are recorded , alongside characteristics of the patient who has completed the survey.

Wave 1 of the National Cancer Patient Experience Survey is limited to patients discharged from cancer care between 01/01/2010 – 31/03/2010.

Data within the file: --PATIENT_PSEUDO_ID (Project specific Pseudonymised Patient ID) GENDER (coded Male, Female) --QUINTILE2010 (Deprivation quintile [1-5], describing the Income Deprivation Domain where 1= least deprived and 5= most deprived) --FINAL_ROUTE (One of eight Routes to Diagnosis- methodology for the assignment of each route is described in Elliss-Brookes L, McPhail S, Greenslade M, Shelton J, Hiom S, Richards M (2012) Routes to diagnosis for cancer – determining the patient journey using multiple routine data sets. British Journal of Cancer 107: 1220–1226.) --AGE (aggregated in 4 categories: <55, 55-64, 65-74, 75+) --STAGE (stage of the cancer coded as I, II, III, IV, missing) --CANCER_SITE (Cancer sites coded in accordance with ICD 10: C00-C14, C15, C16, C18, C19-C20, C25, C33-C34, C43, C49, C50, C54, C56, C61, C64, C67, C73, C82, C83, C85, C90, C91-C95, D05 and ‘all other ICD-10 codes’

Specific disclosure controls applied: --Gender omitted from the data specification in the following cancer sites: • Female only for C50, D05 and C73 • Male only for C49
--Self-reported ethnicity (from the CPES surveys) aggregated into white British / non-white British / not specified. --Self-reported ethnicity omitted for C49, C64, C73 (replaced as “missing”).

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

QResearch linked National Cancer Registration and Analysis Service (NCRAS) cancer registration data contain a record for each notified, registrable tumour, diagnosed or treated in England.

Population-based cancer registration data for all patients diagnosed with a primary tumour (ICD 10 C00-97x, D00-48x) in England. Linked chemotherapy, radiotherapy, hospital admission, diagnostic imaging, primary care diagnosis, and patient experience data

CPRD Aurum linked National Cancer Registration and Analysis Service (NCRAS) cancer registration data contain records for each registrable tumour diagnosed or treated in England, of which the NCRAS has been notified.

The Cancer Outcome and Services Data set (COSD) has been the national standard for reporting cancer in the NHS in England since January 2013.

In January 2013 the COSD replaced the previous National Cancer Dataset as the new national standard for reporting cancer in the NHS in England. It incorporated a revised generic Cancer Registration Dataset (CRDS) and additional clinical and pathology site specific data items relevant to different tumour types.

The COSD specifies the items to be submitted electronically by service providers to the National Cancer Registration and Analysis Service (NCRAS) on a monthly basis. It replaces the existing monthly NCRAS upload and may include separate files from different hospital systems.

The COSD also identifies the items that the NCRAS will obtain from other sources such as Cancer Waiting Times, Cancer Screening Programmes and ONS. (Some items from these other datasets will be included in COSD provider submissions for patient identification and record matching.)

Data is submitted by NHS Providers of Cancer Services and will linked with data from other sources by the NCRAS at patient level using NHS number in order to compile the full dataset.

• Frequency counts of cancer patients receiving radiotherapy, who were resident in England, and began treatment with radiotherapy between 1st April 2016 and 31st March 2017. All data is derived from the patient-level Radiotherapy Treatment Dataset (RTDS) data recorded by National Cancer Registration and Analysis Service (NCRAS). • Data is aggregated using anatomical site groups according to the International Classification of Diseases (ICD) ICD-10 codes, except where otherwise stated. Groupings are identified in tab: ‘Reference – tumour groupings.’ Data is further aggregated by age at treatment start date (presented as 5 year age bands) and sex (male/female). • Treatments are categorised by modality or method of treatment, as (1) external beam radiotherapy (EBRT or Teletherapy) and (2) internal brachytherapy

Whenever it is possible and practicable to do so, data released by PHE will be anonymous and made available under an Open Government License. To render the data anonymous it must be stripped of direct identifiers and privacy by design methods applied in line with the rules layed out in the ISB Anonymisation Standard for Publishing Health and Social Care Data Specification (2013).

National Cancer Registration and Analysis Service (NCRAS). (2018). Cancer Registration: Frequency of tumours diagnosed by route to diagnosis, per Government Office Region (GOR) for 38 cancer sites (2006-2013) [Data set]. Public Health England. https://doi.org/10.25503/3xn3-jp97

Total incident tumours (malignant and in situ) by Route to Diagnosis per Government Office Region. The data is restricted to the England resident population diagnosed between 01/01 2006 and 31/12/2013. 38 cancer sites are identified and the data is split by age at diagnosis (aggregated to 20 year age band) -- TOTAL (total number of patients) --FINAL_ROUTE (One of eight Routes to Diagnosis- methodology for the assignment of each route is described in Elliss-Brookes L, McPhail S, Greenslade M, Shelton J, Hiom S, Richards M (2012) Routes to diagnosis for cancer – determining the patient journey using multiple routine data sets. British Journal of Cancer 107: 1220–1226.) -- DIAGDATEYEAR (Year of diagnosis) -- RTD_GROUPS_BREAKDOWN_2013 (Description of site of tumour (topography)) -- GOR_CODE (in accordance with GOR classifications for April 1996-July 1998. See www.ons.gov.uk/methodology/geography/ukgeographies/administrativegeography/england) -- GOR_NAME (Description of GOR_CODE for each Government Office Region) -- AGE (aggregated in 4 categories: 0-39, 40-59, 60-79, 80+)

CPRD GOLD linked Cancer Patient Experience Survey (CPES) data include information from patients who have responded to the CPES about their cancer journey from their initial GP visit prior to diagnosis, through diagnosis and treatment and to the ongoing management of their cancer.

In the 2022 Annual Report, we present the results for men diagnosed with, or treated for, prostate cancer between 1st April 2020 and 31st March 2021 in England and Wales including: The participation of NHS providers and the completeness and quality of the data submitted to the National Cancer Registration and Analysis Service (NCRAS), NHS Digital and the Wales Cancer Network, Public Health Wales. Patient demographic information and key aspects of the diagnostic and staging process they underwent and the treatments they received. Treatment outcomes (up to two years post-treatment) for men in England and Wales undergoing radical prostatectomy (RP) or radical external beam radiotherapy (EBRT) in 2018-2019. The variation in treatment for men with low-risk, localised disease and high-risk/locally advanced disease in Wales only. In addition, we also present:

This release summarises the diagnoses in 2019 registered by NDRS covering all registerable neoplasms (all cancers, all in situ tumours, some benign tumours and all tumours that have uncertain or unknown behaviours)

CPRD Aurum linked National Radiotherapy Dataset (RTDS) data contain records of radiotherapy services provided since April 2009, including teletherapy and brachytherapy. All radiotherapy delivered in England to patients in NHS facilities, or in private facilities where delivery was funded by the NHS, is included. Brachytherapy delivered for the treatment of non-malignant disease, radiotherapy delivered using unsealed sources, and non-therapeutic exposures delivered using radiotherapy machines (e.g. imaging) are not included.

CPRD GOLD linked Systemic Anti-Cancer Treatment (SACT) data covers chemotherapy treatment for all solid tumour and haematological malignancies, including those in clinical trials. Information is included about programme and regime of treatment, and the outcome for each treatment.

All patients receiving systemic anti-cancer therapies in or funded by the NHS are covered by the dataset.

More information about SACT can be found at (NHS Wales): https://www.datadictionary.wales.nhs.uk/index.html#!WordDocuments/nationalcancerdatastandardsforwalessystemicanticancertherapysact1.htm and https://executive.nhs.wales/functions/networks-and-planning/cancer/clinical-hub/systemic-anti-cancer-therapies-sact/

National Cancer Registration And Analysis Service (NCRAS). (2020). Cancer Registration: Incidence of female breast cancer in London (2002 - 2017) [Data set]. Public Health England. https://doi.org/10.25503/ex4h-zb30 This data set contains the incidence of female breast cancer (C50x, D05x) diagnosed in London, England between the years 2002 to 2017. Variables included: - TUMOUR_PSEUDO_ID (project specific pseudonymised tumour identification number) - AGE_CAT (age at diagnosis; 3 age categories: <40, 40-69, and >=70) - CCG_CODE (code for Clinical Commissioning Group (CCG) of patient residence) - CCG_NAME (name for CCG of patient residence) - DIAGNOSISMONTH (month of diagnosis; values range from 1 (January) to 12 (December)) - DIAGNOSISYEAR (year of diagnosis) - BEHAVIOUR_CODE_DESC (description of tumour behaviour code; 2 values: in situ and malignant) - RANK_VAR (differentiates between first and subsequent relevant tumours (for each patient); 2 values: first and subsequent) Whenever it is possible and practicable to do so, data released by PHE will be anonymous and made available under an Open Government License. To render the data anonymous it must be stripped of direct identifiers and privacy by design methods applied in line with the rules laid out in the ISB Anonymisation Standard for Publishing Health and Social Care Data Specification (2013).

CPRD GOLD linked Quality of Life of Colorectal Cancer Survivors in England: Patient Reported Outcome Measures (PROMs) survey, is a national survey that was commissioned by the Department of Health as a follow-on from the pilot study in July 2011 undertaken to confirm the value of collecting PROMs data on breast, prostate, colorectal and non-Hodgkin’s lymphoma. It includes survey data from 34,467 patients aged 16 years and over with an incident colorectal cancer diagnosis during Jan 2010 Dec 2011. Outcome items in the survey are made up of Euroqol 5-level (EQ-5D), Functional Assessment of Cancer Therapy (FACT), and Social Difficulties Inventory (SDI) items.

CPRD Aurum linked Quality of Life of Cancer Survivors in England: Pilot Survey (2011) was commissioned by the Department of Health as part of the National Cancer Survivorship Initiative (NCSI). The survey was conducted by Quality Health in conjunction with three cancer registries in England. The survey measured the overall quality of life of representative samples of cancer survivors with breast, colorectal cancer, prostate cancer and non-Hodgkin’s lymphoma (NHL) diagnosed during July 2006 - July 2010. Quality of life was assessed at four different time points after diagnosis at approximately one, two, three or five years. As this was a pilot survey, numbers are small and data governance issues will need to be carefully considered on a study by study basis. Outcome items in the survey are made up of Euroqol 5-level (EQ-5D), Functional Assessment of Cancer Therapy (FACT), and Social Difficulties Inventory (SDI) items.